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Abstract
Background—Depressive symptoms are an established predictor of mortality and major adverse
cardiac events (defined as nonfatal myocardial infarction or hospitalization for unstable angina or
urgent/emergency revascularizations) in patients with acute coronary syndrome (ACS). This study
was conducted to determine the acceptability and efficacy of enhanced depression treatment in
patients with ACS.
Methods—A 3-month observation period to identify patients with ACS and persistent depressive
symptoms was followed by a 6-month randomized controlled trial. From January 1, 2005, through
February 29, 2008, 237 patients with ACS from 5 hospitals were enrolled, including 157
persistently depressed patients randomized to intervention (initial patient preference for problem-
solving therapy and/or pharmacotherapy, then a stepped-care approach; 80 patients) or usual care
(77 patients) and 80 nondepressed patients who underwent observational evaluation. The primary
outcome was patient satisfaction with depression care. Secondary outcomes were depressive
symptom changes (assessed with the Beck Depression Inventory), major adverse cardiac events,
and death.
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Results—At the end of the trial, the proportion of patients who were satisfied with their
depression care was higher in the intervention group (54% of 80) than in the usual care group
(19% of 77) (odds ratio, 5.4; 95% confidence interval [CI], 2.2–12.9 [P<.001]). The Beck
Depression Inventory score decreased significantly more (t155=2.85 [P=.005]) for intervention
patients (change, −5.7; 95% CI, −7.6 to −3.8; df=155) than for usual care patients (change, −1.9;
95% CI, −3.8 to −0.1; df=155); the depression effect size was 0.59 of the standard deviation. At
the end of the trial, 3 intervention patients and 10 usual care patients had experienced major
adverse cardiac events (4% and 13%, respectively; log-rank test,  [P=.047]), as well as 5
nondepressed patients (6%) (for the intervention vs nondepressed cohort,  [P=.49]).
Conclusion—Enhanced depression care for patients with ACS was associated with greater
satisfaction, a greater reduction in depressive symptoms, and a promising improvement in
prognosis.
PATIENTS WITH ACUTE COROnary syndrome (ACS) (myocardial infarction or unstable
angina) who report even subsyndromal levels of depressive symptoms are at increased risk
of ACS recurrence or mortality.1,2 This increased risk is observed over many years,3 is
largely independent of other known risk factors for coronary heart disease (CHD),4 is strong,
5 and has a dose-response association.6 The risk is particularly high for those whose
depressive symptoms persist7 or are refractory to treatment.8,9 Although the association is
not found in every study10 or with every ACS patient subgroup,11 systematic reviews,1,2,12
recent international data,13 and other accumulating research indicate that depression is a
marker of increased risk of CHD events and mortality in this patient population. There have
been calls for depression to be recognized as a risk marker14 and recommendations that
patients with CHD be regularly screened for depression and be referred for treatment.15
However, we do not know whether patients with CHD and depressive symptoms, including
many with subsyndromal symptoms, should be treated.
Screening for a reliable CHD risk marker without clear evidence of how to successfully treat
the risk can be problematic.16 In the case of depression, the suffering associated with the
disorder is arguably sufficient justification for treatment. Given the strength of the
observational evidence, however, there have been surprisingly few trials to determine
whether depression can be successfully treated in patients with ACS and the risk of ACS
recurrence or mortality mitigated. The first sufficiently powered trial (Enhancing Recovery
in Coronary Heart Disease [ENRICHD]; conducted in 2481 patients) to test this question
found a significant but modest reduction in depressive symptoms but no mortality difference
between cognitive behavioral depression therapy and usual care.17 A second trial
(Myocardial Infarction and Depression–Intervention Trial [MIND-IT]; conducted in 331
patients) also found significant improvements in depression but no difference in the cardiac
event rate between antidepressant treatment and usual care.18 These results were
disappointing because the Sertraline Antidepressant Heart Attack Randomized Trial
(conducted in 369 patients), although powered only for safety, had shown a promising trend
for 6-month sertraline hydrochloride use to reduce the risk of severe cardiovascular events
compared with placebo.19 Other small trials20 and a post hoc, post-randomization responder
analysis of the ENRICHD trial21 showed similar results. Given these few trials, we do not
yet know whether reducing depressive symptoms improves medical prognosis in patients
with ACS.
The Coronary Psychosocial Evaluation Studies (COPES) intervention trial was designed to
address several reasons why previous trials may not have led to greater reductions in
depressive symptoms and improvements in medical prognosis. First, the COPES trial sought
to better target at-risk patients by using a 3-month observation period after ACS to eliminate
patients whose symptoms spontaneously remit or respond to usual care. This strategy
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identifies patients with persistently elevated depressive symptoms rather than those with a
diagnosis of major depressive disorder only. Second, the COPES trial adopted an approach
to depression care similar to that used for the Improving Mood–Promoting Access to
Collaborative Treatment (IMPACT) trial,22 including stepped care and patient preference.
This approach, tailored to patients with ACS, is designed to increase the acceptance of and
satisfaction with depression treatment in this population because treatment acceptance has
been low in previous trials.23 We hypothesized that the COPES intervention would result in
greater satisfaction with depression care and improved depressive symptoms. We also
compared the rates of major adverse cardiac events (MACEs) and mortality of the depressed
patients in the intervention and usual care groups with those of an observational cohort of
persistently nondepressed but otherwise medically eligible patients.
METHODS
RECRUITMENT, ENROLLMENT, AND INFORMED CONSENT
Participants were recruited at 5 hospital sites (Mount Sinai Hospital and New York
Presbyterian Hospital, New York, New York; and New Haven Hospital, Hospital of St
Raphael, and Veterans Affairs Connecticut Healthcare System−West Haven, New Haven,
Connecticut) from January 1, 2005, through February 29, 2008. Full details of the design
and methods are provided elsewhere.23
Study participants were identified prospectively by monitoring hospital admissions for ACS
diagnoses.24 To ensure that only patients with persistent depressive symptoms were
enrolled, trial eligibility required a score of 10 or higher on the Beck Depression Inventory
(BDI)25 on assessments within 1 week of hospitalization for ACS and 3 months later.
Patients with BDI scores below 5 at both assessment points who met all other eligibility
criteria were included in a nondepressed observational cohort.
Exclusion criteria were assessed at the hospital visit and 3-month follow-up and included
alcohol or other drug dependency, dementia, current or past psychosis or bipolar disorder,
terminal illness, unavailability for follow-up, BDI score of 45 or higher, or suicidality by
self-report or determined during a clinical interview.
The institutional review boards at all institutions approved the protocol, and all participants
provided written informed consent. To ensure equipoise, the description of the study to
patients and their physicians emphasized the possible benefits and limitations of both the
intervention and usual care conditions.
RANDOMIZATION
At each site, eligible patients were randomized on a 1:1 basis within randomly ordered
blocks of 4 or 6 patients according to a table of assignments prepared in advance by the trial
statistician (J.E.S.). Using a Web-based program, project coordinators specified the strata,
initials, and study identification number of the person to be randomized, and the program
issued the group assignment.
INTERVENTION AND USUAL CARE PROTOCOLS
The intervention included the following 5 essential components adapted from the IMPACT
study22: (1) an enhanced care approach, with treatment delivered by a clinical nurse
specialist, psychologist, social worker, and/or psychiatrist; (2) patient choice of
psychotherapy and/or pharmacotherapy; (3) a form of psychotherapy called problem-solving
therapy (PST); (4) a stepped-care approach in which symptom severity was reviewed every
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8 weeks and treatment was augmented according to predetermined decision rules23; and (5)
a standardized instrument used to track depressive symptoms.
Problem-solving therapy, as developed for the IMPACT study, has been described in detail
elsewhere.22,23,26 It is protocol driven, brief, problem focused, and designed to augment the
patient's own skills. Patients are taught how to systematically evaluate and address
individual psychosocial problems. The initiation of and regular engagement in pleasant
activities chosen by the patient is encouraged. Visits initially occurred weekly, in person or
by telephone, with each visit lasting approximately 30 to 45 minutes. Visit frequency was
decreased or increased according to the progress of individual patients and their preference.
Pharmacotherapy treatment choices included sertraline, escitalopram oxalate, venlafaxine
hydrochloride, bupropion hydrochloride, and mirtazapine. A study psychiatrist or nurse
practitioner prescribed appropriate medication following standard clinical practice.
Intervention patients choosing pharmacotherapy were initially seen at 1- to 2-week intervals
for dose titration and thereafter every 3 to 5 weeks as needed for the remainder of the 6-
month trial period. If a patient was already taking an antidepressant, treatment decisions
were coordinated with the prescribing physician. At the end of the trial, patients were
provided with 6 further months of medication if they could not afford it but were referred to
their usual care provider for follow-up. Four patients took advantage of this offer.
Stepped-care decisions for patients randomized to the intervention group were guided by
responses to the 9-item Patient Health Questionnaire,27 administered at each treatment visit
and formally evaluated at 8-week intervals. Patients who did not show prespecified
improvement were offered the choice of switching treatments (eg, from PST to medication),
adding the other treatment, or intensifying the original treatment choice, based on the
treatment team's recommendation (for details, see Burg et al23).
The control condition for the trial was usual care, as defined by the patient's treating
physicians. Physicians of the intervention and usual care patients were informed that their
patients were participating in a trial and that they had elevated depressive symptoms;
physicians were also told whether the patient met the criteria for a major depressive episode.
DATA COLLECTION
At the time of the index ACS hospitalization, demographic, medical history, and prognostic
variables were collected, including left ventricular ejection fraction and Global Registry of
Acute Coronary Events (GRACE) risk score.28 At 3 months, just before randomization, a
structured clinical interview (Depression Interview and Structured Hamilton
questionnaire)29 was conducted by telephone to assess the presence of a current major
depressive episode and psychiatric exclusion criteria. All other measures at hospitalization, 3
months after hospitalization, and at the end of the 6-month intervention (month 9) were
assessed in person. Measures at months 5 and 7 were obtained by telephone. Interviewers
and those collecting medical outcome data were blinded to intervention assignment.
OUTCOME MEASURES
The primary outcome was satisfaction with depression care because previous treatments
may not have been acceptable to patients with CHD.17 Patients were asked, “Over the last 2
months, how would you rate the quality of professional care you have received for your
symptoms of distress or depression?” Patients responded on a 5-point Likert scale (1,
excellent; 5, poor) or indicated that they had received no care for these symptoms.
Depression severity was assessed by the BDI,25 a well-validated depression measure that is
predictive of medical outcomes in this population.30,31 A BDI score of 10 or higher is
consistent with at least mild to moderate depression.
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For each patient-reported hospitalization, supporting documentation was gathered from the
hospital record. Hospital systems were also actively surveyed for events. An end-point
committee of 2 board-certified cardiologists independently reviewed and classified each
hospitalization; in case of disagreement, a third board-certified cardiologist adjudicated the
final end point. Cardiologists were unaware of participants' depression or treatment status.
For participants who could not be contacted or were reported deceased by a relative, the
Social Security Death Index was searched to verify vital status, and death certificates were
obtained. The first occurrence of a MACE (nonfatal myocardial infarction or hospitalization
for unstable angina) or all-cause mortality was recorded.
ADVERSE EVENTS
Participants were asked about unanticipated problems or adverse events at each assessment
(at 3, 5, 7, and 9 months) with the use of a standardized checklist covering major and minor
cardiovascular symptoms and physical and psychiatric symptoms; these were presented
regularly in a blinded fashion to the Data and Safety Monitoring Board.
STATISTICAL ANALYSIS
Differences between the intervention and usual care groups and between the trial
participants and nondepressed cohort at baseline were evaluated using a t test for continuous
variables and χ2 analysis for categorical variables. When baseline medical covariate data
were incomplete for the GRACE and Charlson indexes, a regression-based approach was
used to impute the best linear predicted score based on the available items.
Outcome Analyses—Descriptive statistics based on the raw data at baseline were used to
characterize the sample. Linear and nonlinear (ie, logistic) multilevel repeated-measures
modeling procedures were used to generate full-information maximum-likelihood estimates
of all treatment effects (outcome at 9 months or change in outcome from months 3 to 9, after
the 6-month intervention). By including all subjects and all available data, this approach
yields intent-to-treat estimates that are valid under the assumption that the missing data are
missing at random, conditional on the observed data.32,33 Wald χ2 statistics were used to test
the statistical significance of group differences at 9 months and the differential change
between groups (group×time interaction). The primary outcome was the percentage of
patients who rated their depression care as excellent or very good at 9 months. Change in the
BDI score was a secondary outcome. Effect size was calculated as the group difference in
BDI change divided by the pooled SD at baseline. Kaplan-Meier survival curves for MACEs
were estimated and compared using the log-rank test. All analyses were performed using
SAS statistical software (version 9.2; SAS Institute Inc, Cary, North Carolina), including
PROCs MIXED, NLMIXED, LIFETEST, and PHREG procedures.
Power Analysis—The 2-sided α was set at .05, and power was set at 0.90. The sample
size was chosen to ensure this level of power to detect a 30% group difference (intervention
vs usual care groups) in the proportion of patients who were satisfied with their depression
care at the conclusion of the 6-month trial. This required enrolling 80 patients per group,
allowing for 20% loss (eg, 64 per group with 9-month outcome data would provide a power
of ≥0.93 to detect any 30% group difference in satisfaction, eg, 90% vs 60%, 65% vs 35%,
or 35% vs 5%).
RESULTS
BASELINE CHARACTERISTICS
Patients randomized to the intervention and usual care groups were similar on all baseline
variables (Table 1). In contrast, compared with those in the trial, patients in the
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nondepressed cohort differed on measures of depression (by definition), were less likely to
be female, were more likely to be Hispanic, had more years of education, and were more
likely to be married. Their index ACS was also more likely to be an ST-segment elevation or
a non–ST-segment elevation myocardial infarction than unstable angina. Finally, the
nondepressed cohort had significantly higher GRACE28 scores than the persistently
depressed groups.
TREATMENT PREFERENCES AND INTERVENTION IMPLEMENTATION
Of the 80 patients randomized to intervention, 60 (75%) initially chose PST, 16 (20%) chose
antidepressant medication, and 2 (2.5%) chose both; two patients did not state a treatment
preference (Figure 1). Thirteen patients (16%) did not receive any study treatment. The
mean (SD) number of treatment sessions was 8.2 (5.2) for patients who initially chose PST,
6.0 (3.7) for patients who initially chose antidepressant medication, and 19.5 (6.4) for
patients who initially chose both. The proportion of treatment sessions delivered by phone
ranged between 0% and 94% (mean [SD], 38.8% [36.8%]).
Of the patients who initially chose PST, 6 were additionally prescribed antidepressant
medication during the course of their treatment. Of patients who initially chose
antidepressant medication, 2 later additionally received PST and 1 switched to PST. Within
the first 16 weeks of antidepressant treatment (during which 2 formal step reviews had been
conducted by the entire depression care team), the dosage was increased once for 7 patients
and twice for 2 patients. One patient's treatment was augmented with a second
antidepressant; another patient's dosage was first decreased and later the medication was
switched to another antidepressant type. Of the 2 patients who chose antidepressant
treatment and PST at the beginning of the trial, 1 patient's dosage was changed multiple
times. We did not capture antidepressant increases, switches, or therapy sessions for those
randomized to usual care. Overall, 7 patients terminated treatment before their study
provider advised it.
PREVALENCE OF ANTIDEPRESSANT AND PSYCHOTHERAPY USE BEFORE AND AFTER
THE TRIAL
Approximately one-third of the trial participants (35%) reported taking antidepressants at the
3-month randomization; at the end of the trial this was 48% in the treatment group, but
remained at 30% in the usual care group (odds ratio, 4.48; 95% confidence interval [CI],
1.05–19.2 [P=.04, intention-to-treat estimates]). Participation in psychotherapy was 11%
and 20%, respectively, before randomization; at the end of the trial it had increased to 39%
in the intervention group, with a decline to 12% in the usual care group (odds ratio, 10.1;
95% CI, 2.32–44.3 [P=.002, intention-to-treat estimates; therefore, patient numbers not
presented]).
PRIMARY TRIAL OUTCOME
The percentage of patients reporting depression care as excellent or very good at month 3
(ie, randomization) was modestly and not significantly different between groups (P=.18)
(Table 2). At 9 months, however, 54% of patients in the intervention group reported this
level of satisfaction with depression care compared with 19% in the usual care group (odds
ratio, 5.4; 95% CI, 2.2–12.9 [P<.001, intention-to-treat estimates]).
SECONDARY TRIAL OUTCOMES
Depressive symptoms decreased significantly in both the intervention (mean change, −5.7;
95% CI, −7.6 to −3.8) and usual care (mean change, −1.9; 95% CI, −3.8 to −0.1) groups
(Table 3). The group difference in depressive symptom decrease was also significant (mean
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group difference, −3.8; 95% CI, −6.5 to −1.2; t155=2.85 [P=.005]), representing a
depression effect size of 0.59 (95% CI, 0.18–1.00). Table 3 also shows that the depressive
symptom effects seemed to generalize across men, women, Hispanic patients, and African
American patients. In an analysis of the 3-, 5-, 7- and 9-month depressive symptoms, group
differences emerged 4 months into the trial (at month 7; t155=2.88 [P=.004]) and remained
significant at the end of the trial (t155=2.99 [P=.003]).
Patient-reported adverse events were similar overall between the intervention and usual care
groups, except that the usual care patients were significantly more likely to report
experiencing a non–depression-related psychiatric problem than those in the intervention
group (68 vs 59;  [P=.02]).
Patients in the intervention group had fewer MACE events (3 events [4%]) than did those in
the usual care group (10 [13%]) or the nondepressed observational cohort (5 [6%]). Figure 2
shows the Kaplan-Meier curves for the 3 groups (log-rank test for the usual care vs
intervention groups,  [P=.047]; for the intervention vs nondepressed group, 
[P=.049]. No significant site differences were detected for any of the primary or secondary
outcomes.
COMMENT
In light of the damaging impact of depression on quality of life and prognosis in patients
with CHD,1,30 rates of detection and effective treatment for depression remain unacceptably
low in this patient population.20 It was in this spirit that the COPES trial was undertaken.
The enhanced-care, patient-preference, stepped approach used herein was associated with
substantial improvement in satisfaction with depression care and a significant reduction in
depressive symptoms. In addition, although the study was not powered for this outcome, the
intervention led to a promising difference in MACEs between randomized groups, with the
MACE rate in the intervention group resembling that in the nondepressed cohort.
LIMITATIONS
First, patients selected for this trial did not include all patients with ACS. We excluded those
with cognitive impairments, other life-threatening conditions, and, most important, other
psychiatric conditions such as alcohol or other drug dependence and bipolar disorder.
Because these comorbid conditions are highly prevalent in depressed patients, our findings
might not be applicable to all patients with ACS and depressive symptoms. Second, we had
a relatively small sample size, and the MACE rate was, expectedly, quite small. Thus,
further trials of enhanced depression care are required to determine whether this type of
treatment can improve post-ACS prognosis. Third, our patients were not blinded to their
treatment status. We made every effort to blind the endpoint committee and the outcome
assessors by asking patients not to reveal their group and by ensuring that assessors were not
in contact with the therapist team, but this is only a single-blind trial. Fourth, we chose usual
care as our control condition rather than placebo or another active control, such as clinical
management. Thus, we did not account for nonspecific effects of treatment. Fifth, 13 of the
80 patients randomized to treatment never attended a first depression care visit. Another 7
terminated treatment before their care provider advised it, suggesting that, although the
acceptance of our depression intervention was more than 50%, there is room for
improvement. Recent studies using telephone-delivered cognitive behavioral therapy34 and
combined psychotherapy with pharmacotherapy by telephone35,36 provided suggestions for
novel delivery methods to further test in patients with ACS. Sixth, we did not collect cost
data, which would have aided in the evaluation of this intervention. Finally, our 6-month
treatment may have been too brief; we saw significant differences in depressive symptoms
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only after 4 months of treatment. The American College of Physicians37 recommended that
clinicians continue treatment for 4 to 9 months after a satisfactory response in patients with a
first episode of major depressive disorder. For patients who have had 2 or more episodes of
depression, an even longer duration of therapy may be beneficial. The depression and
cardiac outcomes reported herein might be strengthened by longer depression treatment.
COMPARISON OF COPES WITH OTHER DEPRESSION INTERVENTION TRIALS IN
PATIENTS AFTER ACS
Although some previous trials have shown statistically significant reductions in depressive
symptoms, there were no improvements in cardiovascular outcomes.20 One possible
explanation is that the depression treatment effects resulting from the modalities tested were
not large enough to alter the increased risk of cardiovascular events and mortality conferred
by depression.38 In fact, previous trials had 1 common finding: only clinically modest
depression differences between the treatment and control groups.20 One plausible reason for
this finding is that the treatments were unacceptable to patients with CHD.17 A patient's
willingness to engage in, adhere to, and continue depression treatment can determine
whether the treatment succeeds or fails. Most of the depression interventions used in
previous trials involving patients with CHD were originally validated with treatment-
seeking out-patients with psychiatric problems; therefore, acceptance by the broader
population of patients with CHD cannot be assumed.39 Previous studies have shown that
fewer patients drop out of PST compared with other psychological therapies.40
Another possible explanation for the lack of improved cardiac prognosis with previously
tested depression interventions is that the treatments were not sufficiently powerful.38
Recent systematic reviews of single-modality antidepressant41,42 or psychotherapy43
treatments in other patient populations showed only modest efficacy compared with placebo
or usual care. Larger effect sizes have been found with multimodal44,45 or stepped-care22,46
depression treatment interventions. Until this trial, enhanced-care, stepped algorithms had
not been tested in patients with CHD, but the results in other medical populations were
promising.22,47–49 We thus chose to test this treatment modality in the COPES trial. We
found a reasonable depression effect size (0.59) that compares favorably with those of
previous interventions designed to reduce depression in patients with CHD (0.20–0.38).20
Large reductions in depressive symptoms in the control group are an issue in trials enrolling
depressed patients with and without ACS.38,41 Depression is a relapsingremitting disease50;
hence, substantial reductions in symptoms and/or spontaneous remission can occur. Also,
medical providers increasingly recognize depressive symptoms in patients with ACS, and
some patients' symptoms respond to the conventional depression treatment offered.21 For
these reasons, we chose to include a 3-month observation period to identify patients with
persistent depressive symptoms and thereby decrease the likelihood of a large reduction in
depressive symptoms in the control group. We had a smaller reduction in depressive
symptoms in the control group compared with other trials of depressed patients with CHD,
possibly as a result of this strategy.
It is not known whether only a subset of patients who are depressed after ACS is at risk for
ACS recurrence or mortality.7,51,52 We excluded more patients than we enrolled because of
depressive symptom improvement, and this could be viewed as a limitation because we
targeted a small sample without psychiatric diagnoses. Most observational cohort studies
demonstrating depression-associated risk of ACS recurrence or mortality used a BDI score
of 10 or higher to characterize depression4 rather than conventional psychiatric diagnoses.53
Participants with persistently elevated BDI scores (≥10) in these studies were found to be at
risk of death.6 In the COPES trial, we similarly targeted patients with a BDI score of 10 or
higher rather than just those meeting the diagnostic criteria for a psychiatric disorder. As
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expected with initial tests of whether reducing a risk factor offsets cardiac event rates, the
impact of depression treatments on MACEs and other cardiac risks is disparate among the
trials of depression treatment in patients with CHD.54 The results reported herein for the
COPES trial offer promising approaches for a larger trial.
Treating depression effectively in patients with CHD may be daunting, but trials to
determine the best way to manage these 2 highly prevalent and disabling diseases55 need to
continue. In the secondary prevention of cardiovascular disease, stepped-care models of
depression treatment with patient preference may offer an effective approach to improve
depressive symptoms and satisfaction with care; whether this type of treatment can
definitively improve cardiac prognosis awaits a larger trial.
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Patient flowchart. BDI indicates Beck Depression Inventory.
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Kaplan-Meier survival curves for major adverse cardiac events in the Coronary Psychosocial
Evaluation Studies for randomized patients and the nondepressed cohort. *The number at
risk at 9 months includes those who were evaluated during the ninth month.
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Table 2
Satisfaction With Depression Care 3 and 9 Months After ACSa
Variable
Usual Care Group
(n=77) Intervention Group (n=80) OR (95% CI) P Value
Rated depression care as excellent or very good at 3
mo, % (95% CI)b 13.2 (6.5–19.6) 21.6 (12.9–29.7) 1.8 (0.8–4.5) .18
Rated depression care as excellent or very good at 9
mo, % (95% CI)b 18.8 (10.4–26.7) 54.2 (41.9–63.6) 5.4 (2.2–12.9) <.001
Patients receiving no care at 3 mo, No. (%) 56/76 (74) 53/74 (72) … …
Patients receiving no care at 9 mo, No. (%) 43/69 (62) 19/70 (27) … …
Abbreviations: ACS, acute coronary syndrome; CI, confidence interval; ellipses, not applicable; OR, odds ratio.
a
Data on depression care were missing for 7 patients at 3 months and for 18 patients at 9 months.
b
Numbers of patients are not provided because these percentages are derived from an intent-to-treat, multilevel, repeated-measures logistic
regression analysis.
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